Boehringer, Zealand reframe diabetes pact

Share this article:

Boehringer Ingeleim and Zealand Pharma are still diabetes partners but have redefined the relationship they began in 2011.

The companies said in a joint statement that they will continue to collaborate on novel glucagon/GLP-1 dual agonists for diabetes or obesity, but ZP2929 is no longer the keystone compound.

Instead, Zealand gets all rights to ZP2929, and another agent will be swapped in. The companies said the original financial collaboration arrangements are staying put.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.